The table below shows RECURSION PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$6.47M
$5.17M
$19.22M
$14.74M
$26.08M
$14.42M
Cost of revenue
$12.49M
$14.69M
$20.16M
$21.83M
$12.08M
$9.20M
Gross profit
-
-
-
-
-
-
R&D
$87.90M
$121.06M
$128.64M
$129.63M
$74.60M
$73.93M
RXRX annual revenue (10-K history)
RECURSION PHARMACEUTICALS, INC. reported annual revenue of $74.68M for fiscal year 2025. That is up 26.9% from $58.84M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $2.32M (FY 2019) to $74.68M. Figures come from the company's audited annual reports as filed with the SEC.
